Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
- Hidenori Arai,
- Shizuya Yamashita,
- Koutaro Yokote,
- Eiichi Araki,
- Hideki Suganami,
- Shun Ishibashi,
Atherosclerosis 2017 Jun 24;261:144-152. Epub 2017 Mar 24.
Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.